Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort
Overview
Authors
Affiliations
Background: Little is known about complications after major duodenopancreatic surgery for duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). Therefore, the incidence and severity of complications after major surgery for MEN1-related dpNETs were assessed.
Methods: Patients were selected from the population-based Dutch MEN1 database if they had undergone a Whipple procedure or total pancreatectomy from 2003 to 2017. Complications were graded according to the Clavien-Dindo classification (grade III or higher complications were considered a severe complication) and definitions from the International Study Group of Pancreatic Surgery. The Cumulative Complication Index (CCI) was calculated as the sum of all complications weighted for their severity. Univariable logistic regression was performed to assess potential associations between predictor candidates and a severe complication.
Results: Twenty-seven patients (median age 43 years) underwent a major duodenopancreatic resection, including 14 Whipple procedures and 13 total pancreatectomies. Morbidity and mortality were 100% (27/27) and 4% (1/27), respectively. A severe complication occurred in 17/27 (63%) patients. The median CCI was 47.8 [range 8.7-100]. Grade B/C pancreatic fistulas, delayed gastric emptying, bile leakage, hemorrhage, and chyle leakage occurred in 7/14 (50%), 10/27 (37%), 1/27 (4%), 7/27 (26%), 3/27 (11%) patients, respectively. Patients with a severe complication had longer operative time and higher blood loss. After Whipple, new-onset endocrine and exocrine insufficiency occurred in 1/13 and 9/14 patients, respectively.
Conclusions: Major duodenopancreatic surgery in MEN1 is associated with a very high risk of severe complications and cumulative burden of complications and should therefore be reserved for a select subgroup of patients with MEN1-related dpNETs.
[Individualized approach for MEN1-associated duodenopancreatic neuroendocrine neoplasms].
Manoharan J, Albers M, Bartsch D Chirurgie (Heidelb). 2024; 95(3):207-215.
PMID: 38180518 DOI: 10.1007/s00104-023-01994-8.
Approach to the Patient: Insulinoma.
Hofland J, Refardt J, Feelders R, Christ E, de Herder W J Clin Endocrinol Metab. 2023; 109(4):1109-1118.
PMID: 37925662 PMC: 10940262. DOI: 10.1210/clinem/dgad641.
Wang K, Xiao J, Li L, Li X, Yang Y, Liu Z Front Nutr. 2023; 10:1128864.
PMID: 37545584 PMC: 10399236. DOI: 10.3389/fnut.2023.1128864.
van Vliembergen E, Eijkelenkamp H, Valk G, Vriens M, Meijer G, Intven M Front Endocrinol (Lausanne). 2023; 14:994370.
PMID: 37305036 PMC: 10250693. DOI: 10.3389/fendo.2023.994370.
Multiple endocrine neoplasia type 1 involving both the liver and lung: a case report.
Lai J, Huang Y, Wu J, Cheng H, Qiu F World J Surg Oncol. 2022; 20(1):151.
PMID: 35538538 PMC: 9088025. DOI: 10.1186/s12957-022-02622-1.